Drugs & Aging

, Volume 21, Issue 1, pp 7–17 | Cite as

Effects of Calcium Supplementation on Circulating Lipids

Potential Pharmacoeconomic Implications
Leading Article


For about a century there has been recognition that calcium and lipids bind to one another in the gut, each interfering with the other’s absorption. Calcium also causes malabsorption of bile acids, which is likely to contribute further to malabsorption of fat. High dietary calcium intakes may also have stimulatory effects on lipolysis. These mechanisms provide a basis for hypothesising that calcium supplementation may impact on circulating lipid concentrations, and there is now a significant amount of observational and trial data indicating that this is the case. The largest randomised controlled trial of calcium effects on lipids was carried out in 223 healthy postmenopausal women, and found that low density lipoprotein-cholesterol (LDL-C) decreased 6.3% and high density lipoprotein-cholesterol (HDL-C) increased by 7.3% at 1-year. The resultant 16.4% increase in HDL-C/LDL-C ratio would be predicted to reduce cardiovascular event rates by 20–30%, which is consistent with the available observational data. There are no trial data addressing this question and it is possible that other lipid-lowering agents, such as hydroxymethylglutaryl coenzyme A reductase inhibitors, might impact on cardiac event rates by mechanisms other than by lowering cholesterol levels. Therefore, caution is appropriate in incorporating these findings into clinical practice, but the balance of evidence suggests that calcium is a cost-effective adjunct to the dietary management of hyperlipidaemia.



This work has been supported by the Health Research Council of New Zealand. The author has received research funding from and acted as a consultant for New Zealand Milk and Mission Pharmacal Co., San Antonio, Texas, USA.


  1. 1.
    Yacowitz H, Fleischman AI, Bierenbaum ML. Effects of oral calcium on serum lipids in man. BMJ 1965; 1: 1352–4PubMedCrossRefGoogle Scholar
  2. 2.
    Bierenbaum ML, Fleischman AI, Raichelson RI. Long-term human studies on the lipid effects of oral calcium. Lipids 1972; 7: 202–6PubMedCrossRefGoogle Scholar
  3. 3.
    Mitchell WD, Fyfe T, Smith DA. The effect of oral calcium on cholesterol metabolism. J Atheroscler Res 1968; 8: 913–22PubMedCrossRefGoogle Scholar
  4. 4.
    Carlson LA, Olsson AG, Oro L, et al. Effects of oral calcium on serum cholesterol and triglycerides in patients with hyperlipidemia. Atherosclerosis 1971; 14: 391–400PubMedCrossRefGoogle Scholar
  5. 5.
    Albanese AA, Edelson AH, Woodhull ML, et al. Effect of a calcium supplement on serum cholesterol, calcium, phosphorus and bone density of normal healthy elderly females. Nutr Rep Int 1973; 8: 119–30Google Scholar
  6. 6.
    Bhattacharyya AK, Thera C, Anderson JT, et al. Dietary calcium and fat: effect on serum lipids and fecal excretion of cholesterol and its degradation products in man. Am J Clin Nutr 1969; 22: 1161–74PubMedGoogle Scholar
  7. 7.
    Groot PHE, Grose WFA, Dijkhuis-Stoffelsma R, et al. The effect of oral calcium carbonate administration on serum lipoproteins of children with familial hypercholesterolaemia (type II-A). Eur J Pediatr 1980; 135: 81–4PubMedCrossRefGoogle Scholar
  8. 8.
    Bell L, Halstenson CE, Halstenson CJ, et al. Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med 1992; 152: 2441–4PubMedCrossRefGoogle Scholar
  9. 9.
    Denke MA, Fox MM, Schulte MC. Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. J Nutr 1993; 123: 1047–53PubMedGoogle Scholar
  10. 10.
    Bostick RM, Fosdick L, Grandits GA, et al. Effect of calcium supplementation on serum cholesterol and blood pressure: a randomized, double-blind, placebo-controlled, clinical trial. Arch Fam Med 2000; 9: 31–8PubMedCrossRefGoogle Scholar
  11. 11.
    Reid IR, Mason B, Home A, et al. Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. Am J Med 2002; 112: 343–7PubMedCrossRefGoogle Scholar
  12. 12.
    Zemel MB, Shi H, Greer B, et al. Regulation of adiposity by dietary calcium. FASEB J 2000; 14: 1132–8PubMedGoogle Scholar
  13. 13.
    Kelly KA, Gimble JM. 1,25-dihydroxy vitamin d-3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures. Endocrinology 1998; 139: 2622–8PubMedCrossRefGoogle Scholar
  14. 14.
    Grey AB, Evans MC, Stapleton JP, et al. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Ann Intern Med 1994; 121: 745–9PubMedGoogle Scholar
  15. 15.
    Davies KM, Heaney RP, Recker RR, et al. Calcium intake and body weight. J Clin Endocrinol Metab 2000; 85: 4635–8PubMedCrossRefGoogle Scholar
  16. 16.
    McCarron DA, Morris CD, Henry HJ, et al. Blood pressure and nutrient intake in the United States. Science 1984; 224: 1392–8PubMedCrossRefGoogle Scholar
  17. 17.
    Comstock G. Water hardness and cardiovascular diseases. Am J Epidemiol 1979; 110: 375–400PubMedGoogle Scholar
  18. 18.
    Knox EG. Ischaemic-heart-disease mortality and dietary intake of calcium. Lancet 1973; II: 1465–7CrossRefGoogle Scholar
  19. 19.
    van der Vijver LPL, van der Waal MAE, Wterings KGC, et al. Calcium intake and 28-year cardiovascular and coronary heart disease mortality in Dutch civil servants. Int J Epidemiol 1992; 21: 36–9PubMedCrossRefGoogle Scholar
  20. 20.
    Bostick RM, Kushi LH, Wu Y, et al. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol 1999; 149: 151–61PubMedCrossRefGoogle Scholar
  21. 21.
    Iso H, Stampfer MJ, Manson JE, et al. Prospective study of calcium, potassium, and magnesium intake and risk of stroke in women. Stroke 1999; 30: 1772–9PubMedCrossRefGoogle Scholar
  22. 22.
    Griffith LE, Guyatt GH, Cook RJ, et al. The influence of dietary and nondietary calcium supplementation on blood pressure: an updated metaanalysis of randomized controlled trials. Am J Hypertens 1999; 12: 84–92PubMedCrossRefGoogle Scholar
  23. 23.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  24. 24.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7PubMedCrossRefGoogle Scholar
  25. 25.
    Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk in individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22CrossRefGoogle Scholar
  26. 26.
    Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37–45PubMedCrossRefGoogle Scholar
  27. 27.
    Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90: 139–43PubMedCrossRefGoogle Scholar
  28. 28.
    Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999; 340: 101–7PubMedCrossRefGoogle Scholar
  29. 29.
    Jones G, Nguyen T, Sambrook PN, et al. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994; 4: 277–82PubMedCrossRefGoogle Scholar
  30. 30.
    Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6PubMedCrossRefGoogle Scholar
  31. 31.
    Meier CR, Schleinger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205–10PubMedCrossRefGoogle Scholar
  32. 32.
    van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285: 1850–5PubMedCrossRefGoogle Scholar
  33. 33.
    Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet 2001; 357: 509–12PubMedCrossRefGoogle Scholar
  34. 34.
    Curhan GC, Willett WC, Rimm EB, et al. Family history and risk of kidney stones. J Am Soc Nephrol 1997; 8: 1568–73PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of MedicineUniversity of AucklandAucklandNew Zealand

Personalised recommendations